Related Experiment Video

Updated: Aug 15, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Endocrine therapy for prostate cancer

Jan-Erik Damber1

  • 1Department of Urology, Sahlgrenska University Hospital, Goteborg, Sweden. jan-erik.damber@urology.gu.se

Acta Oncologica (Stockholm, Sweden)
|September 17, 2005
PubMed

Insights

Endocrine therapy for prostate cancer, targeting androgenic effects, is increasingly explored as adjuvant treatment. Early hormonal intervention may offer survival benefits, with discussions on optimal timing and combination strategies.

Area of Science:

  • Oncology
  • Endocrinology
  • Urology

Background:

  • Endocrine therapy for prostate cancer primarily targets androgenic stimulation of tumor cells.
  • Current use is mainly for advanced stages, but early application is gaining interest.

Purpose of the Study:

  • To review the principles and evolving applications of endocrine therapy in prostate cancer management.
  • To discuss the potential benefits of early and adjuvant endocrine treatment, including timing and combination strategies.

Main Methods:

  • Overview of established endocrine treatment modalities for prostate cancer.
  • Discussion of GnRH agonists/antagonists, antiandrogens, and oestrogens.
  • Exploration of treatment timing, combined androgen blockade, and intermittent therapy.

Main Results:

  • Non-steroidal antiandrogens offer a side-effect profile favorable for adjuvant therapy compared to castration.
  • Early endocrine treatment may confer survival advantages in specific prostate cancer stages.
  • Optimal timing, combination therapy, and intermittent approaches are key considerations.

Conclusions:

  • Endocrine therapy is expanding beyond advanced prostate cancer, with potential as adjuvant treatment after localized therapies.
  • Further research into optimal timing and combination strategies is warranted to maximize survival benefits.
  • Non-steroidal antiandrogens represent a promising option for early and adjuvant endocrine management.

More Related Videos

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

An Orthotopic Murine Model of Human Prostate Cancer Metastasis06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Regulation of Hormone Secretion01:19

Regulation of Hormone Secretion

Regulation of hormone secretion is a finely tuned orchestration driven by various types of stimuli, encompassing neural, humoral, and hormonal signals. Environmental cues instigate neural stimuli, where action potentials traverse nerve fibers to reach their designated targets. An illustrative scenario is the body's response to stress, wherein the sympathetic nervous system releases epinephrine from the adrenal glands, inducing the well-known 'fight or flight' reaction.
Humoral stimuli,...
Target Cell Response to Hormones01:22

Target Cell Response to Hormones

Hormones intricately bind to receptors on the surface or within target cells, initiating a cascade of cellular responses.
Notably, the cellular response can be regulated by altering the number of receptors expressed in the cell. For example, prolonged exposure to elevated hormone levels results in a gradual decline or down-regulation in the number of receptors for that specific hormone on the cell surface. Conversely, in response to low hormone levels, cells may use up-regulation, producing an...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...